Sarecycline
- TRADE NAME: Seysara (Allergan)
- INDICATIONS: indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older.
- CLASS: Antibiotic, Antibiotic; tetracycline
- HALF-LIFE: 21–22 hours
FDA APPROVAL DATE: 10/01/2018
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:PREGNANCY CATEGORY: N/A
may cause fetal harm
Please login to see the rest of this drug profile
SKIN.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
OTIC.
RESPIRATORY.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric